Merck Debt to Equity Ratio 2010-2024 | MKKGY
Current and historical debt to equity ratio values for Merck (MKKGY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Merck debt/equity for the three months ending June 30, 2024 was 0.27.
Merck Debt/Equity Ratio Historical Data |
Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
2024-06-30 |
$22.89B |
$30.82B |
0.74 |
2024-03-31 |
$23.27B |
$30.48B |
0.76 |
2023-12-31 |
$23.53B |
$28.96B |
0.81 |
2023-09-30 |
$23.52B |
$30.80B |
0.76 |
2023-06-30 |
$24.00B |
$29.19B |
0.82 |
2023-03-31 |
$24.05B |
$28.16B |
0.85 |
2022-12-31 |
$23.73B |
$27.40B |
0.87 |
2022-09-30 |
$22.76B |
$28.54B |
0.80 |
2022-06-30 |
$24.15B |
$27.70B |
0.87 |
2022-03-31 |
$26.09B |
$25.80B |
1.01 |
2021-12-31 |
$28.33B |
$25.34B |
1.12 |
2021-09-30 |
$27.31B |
$24.39B |
1.12 |
2021-06-30 |
$28.66B |
$23.33B |
1.23 |
2021-03-31 |
$30.03B |
$22.89B |
1.31 |
2020-12-31 |
$28.31B |
$19.44B |
1.46 |
2020-09-30 |
$29.50B |
$21.04B |
1.40 |
2020-06-30 |
$28.40B |
$19.85B |
1.43 |
2020-03-31 |
$28.84B |
$20.52B |
1.41 |
2019-12-31 |
$29.01B |
$20.06B |
1.45 |
2019-09-30 |
$26.56B |
$20.22B |
1.31 |
2019-06-30 |
$24.72B |
$19.75B |
1.25 |
2019-03-31 |
$23.90B |
$20.08B |
1.19 |
2018-12-31 |
$23.21B |
$20.35B |
1.14 |
2018-09-30 |
$23.71B |
$17.84B |
1.33 |
2018-06-30 |
$24.97B |
$17.76B |
1.41 |
2018-03-31 |
$25.90B |
$17.34B |
1.49 |
2017-12-31 |
$24.36B |
$15.90B |
1.53 |
2017-09-30 |
$25.90B |
$16.21B |
1.60 |
2017-06-30 |
$25.31B |
$15.14B |
1.67 |
2017-03-31 |
$25.44B |
$15.43B |
1.65 |
2016-12-31 |
$26.78B |
$15.55B |
1.72 |
2016-09-30 |
$26.51B |
$14.50B |
1.83 |
2016-06-30 |
$27.30B |
$14.52B |
1.88 |
2016-03-31 |
$27.15B |
$13.86B |
1.96 |
2015-12-31 |
$27.91B |
$14.27B |
1.96 |
2015-09-30 |
$20.30B |
$15.60B |
1.30 |
2015-06-30 |
$17.59B |
$15.38B |
1.14 |
2015-03-31 |
$19.12B |
$15.60B |
1.23 |
2014-12-31 |
$18.89B |
$15.69B |
1.20 |
2014-09-30 |
$14.51B |
$15.64B |
0.93 |
2014-06-30 |
$14.08B |
$15.39B |
0.92 |
2014-03-31 |
$13.38B |
$15.41B |
0.87 |
2013-12-31 |
$12.95B |
$14.70B |
0.88 |
2013-09-30 |
$13.97B |
$14.28B |
0.98 |
2013-06-30 |
$14.70B |
$13.76B |
1.07 |
2013-03-31 |
$15.11B |
$13.89B |
1.09 |
2012-12-31 |
$14.44B |
$13.39B |
1.08 |
2012-09-30 |
$14.65B |
$13.22B |
1.11 |
2012-06-30 |
$14.60B |
$13.54B |
1.08 |
2012-03-31 |
$0.00B |
|
0.00 |
2011-12-31 |
$16.20B |
$14.62B |
1.11 |
2011-09-30 |
$0.00B |
|
0.00 |
2011-06-30 |
$16.60B |
$14.90B |
1.11 |
2011-03-31 |
$0.00B |
|
0.00 |
2010-12-31 |
$0.00B |
|
0.00 |
2010-09-30 |
$16.10B |
$13.59B |
1.19 |
2010-06-30 |
$0.00B |
|
0.00 |
2010-03-31 |
$0.00B |
|
0.00 |
2009-12-31 |
$0.00B |
|
0.00 |
2009-09-30 |
$0.00B |
|
0.00 |
2009-06-30 |
$0.00B |
|
0.00 |
2009-03-31 |
$0.00B |
|
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$21.306B |
$22.719B |
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
|